SCHEMBL745787

SCHEMBL745787

NP(N)(=S)N1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6040985 0.93
SCHEMBL6041036 0.90 LMNA (0.35)
SCHEMBL6041009 0.86
SCHEMBL10931717 0.86 ABCB11 (0.50)
SCHEMBL6048121 0.75 ABCB11 (0.33)
SCHEMBL6041022 0.73 FAAH (0.32)
SCHEMBL6041027 0.73 GAA (0.43)
SCHEMBL433171 0.65
SCHEMBL3084917 0.65 ABCB11 (0.71)
SCHEMBL3076515 0.62 LMNA (0.67)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240118285-A1 COMPOSITIONS AND METHODS FOR T-CELL RECEPTOR IDENTIFICATION ROOTPATH GENOMICS, INC. 2024-04-11 US claimed
EP-4232080-A1 COMPOSITIONS AND METHODS FOR T-CELL RECEPTOR IDENTIFICATION Rootpath Genomics, Inc. (US) 2023-08-30 EP claimed
WO-2022087380-A1 COMPOSITIONS AND METHODS FOR T-CELL RECEPTOR IDENTIFICATION ROOTPATH GENOMICS, INC. (US) 2022-04-28 WO claimed
CN-113825771-A Antibodies against claudin 18A2 and uses thereof 齐鲁制药有限公司 2021-12-21 CN claimed
WO-2020228806-A1 ANTIBODY AGAINST CLAUDIN 18A2 AND USE THEREOF 齐鲁制药有限公司 2020-11-19 WO claimed
EP-2649998-B1 Prolyl hydroxylase inhibitors AERPIO THERAPEUTICS INC (US) 2015-03-04 EP claimed
US-8883832-B2 Compounds, compositions, and methods for preventing metastasis of cancer cells AERPIO THERAPEUTICS INC. (US) 2014-11-11 US claimed
US-20140249100-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS AERPIO THERAPEUTICS INC. (US) 2014-09-04 US claimed
US-8569348-B2 Compounds, compositions, and methods for preventing metastasis of cancer cells AERPIO THERAPEUTICS INC. (US) 2013-10-29 US claimed
EP-2649998-A1 Prolyl hydroxylase inhibitors Aerpio Therapeutics Inc. (US) 2013-10-16 EP claimed
US-20120128625-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS EyePoint, Inc. 2012-05-24 US claimed
US-20120121692-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER SHANDONG UNIVERSITY (CN) 2012-05-17 US claimed
EP-2451279-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS Akebia Therapeutics Inc. (US) 2012-05-16 EP claimed
EP-2429292-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER Georgia State University Research Foundation, Inc. (US) 2012-03-21 EP claimed
US-20110111058-A1 METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA AERPIO THERAPEUTICS LLC 2011-05-12 US claimed
WO-2011005330-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS AKEBIA THERAPEUTICS INC. (US) 2011-01-13 WO claimed
WO-2010129858-A1 COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR THE TREATMENT OF CANCER GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) 2010-11-11 WO claimed
US-12043664-B2 Methods for treating vascular leak syndrome and cancer EyePoint Pharmaceuticals, Inc. (US) 2024-07-23 US disclosed
WO-2001000196-A2 MIRTAZAPINE FOR WEIGHT GAIN IN WASTING DISEASES UNIVERSITY OF SOUTH FLORIDA (US) 2001-01-04 WO disclosed
WO-2000010391-A1 THE USE OF ADENOSINE A3 RECEPTOR ANTAGONISTS TO INHIBIT TUMOR GROWTH MEDCO RESEARCH, INC. (US) 2000-03-02 WO disclosed